Download PDF
Thromb Haemost 1991; 65(01): 020-024
DOI: 10.1055/s-0038-1647447
Original Article
Schattauer GmbH Stuttgart

Heparin Cofactor II Deficiency in Renal Allograft Recipients: No Correlation with the Development of Thrombosis

P Toulon
1   Laboratoire d’Hémostase, Hôpital Broussais, Paris, France
,
L Moulonguet-Doleris
2   Clinique Néphrologique, Hôpital Broussais, Paris, France
,
J M Costa
1   Laboratoire d’Hémostase, Hôpital Broussais, Paris, France
,
M Aiach
1   Laboratoire d’Hémostase, Hôpital Broussais, Paris, France
› Author Affiliations
Further Information

Publication History

Received 27 April 1990

Accepted after revision 21 August 1990

Publication Date:
02 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Heparin cofactor II (HC II) is a thrombin inhibitor in human plasma which displays great similarities with antithrombin III (AT III). Hereditary HC II deficiency was recently reported to be associated with thrombophilia. Since thromboembolism constitutes an important post-operative complication after renal transplantation, we measured HC II and AT III in the plasma of 118 healthy renal allograft recipients (RAR) and found stable low HC II and high AT III levels. Administration of azathioprine (AZA), cyclosporine A (CSA) or both as immunosuppressive therapy did not affect HC II levels, but CSA seems to have raised plasma AT III. The proportion of patients with HC II deficiency was significantly higher in RAR than the proportion we previously found (11) in healthy individuals (16.9% vs 1.5%). However, the proportions with low plasma HC II were not different in healthy RAR and in ten RAR with thrombotic events, suggesting that in transplanted patients, HC II deficiency is not in itself a risk factor for the development of thrombosis.

 

  • References

  • 1 Tollefsen DM, Blank MK. Detection of a new heparin-dependent inhibitor of thrombin in human plasma. J Clin Invest 1981; 68: 589-596
    CrossrefPubMedGoogle Scholar
  • 2 Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6716
    PubMedGoogle Scholar
  • 3 Griffith MJ, Noyes CM, Church FC. Reactive site peptide structural similarity between heparin cofactor II and antithrombin III. J Biol Chem 1985; 260: 2218-2225
    PubMedGoogle Scholar
  • 4 Blinder MA, Marasa JC, Reynolds CH, Deaven LL, Tollefsen DM. cDNA sequence, chromosome localization, restriction fragment length polymorphism, and expression in Escherichia coli. Biochemistry 1988; 27: 752-759
    CrossrefPubMedGoogle Scholar
  • 5 Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248: 6490-6505
    PubMedGoogle Scholar
  • 6 Carrell RW, Christey PB, Boswell DR. Serpins: antithrombin and other inhibitors of coagulation and fibrinolysis. Evidence from amino acid sequences. In: Thrombosis and Haemostasis Verstraete M, Vermylen J, Lijnen R, Amout J. (eds) Leuven University Press; Leuven: 1987: 1-15
  • 7 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516-530
    PubMedGoogle Scholar
  • 8 Tran TH, Marbet GA, Duckert F. Association of hereditary heparin cofactor II deficiency with thrombosis. Lancet 1985; 02: 413-414
    PubMedGoogle Scholar
  • 9 Sié P, Dupouy D, Pichon J, Boneu B. Constitutional heparin cofactor II deficiency associated with recurrent thrombosis. Lancet 1985; 02: 414-416
    PubMedGoogle Scholar
  • 10 Bertina RM, van der Linden IK, Engeser L, Muller HP, Brommer EJ P. Hereditary heparin cofactor II deficiency and the risk of development of thrombosis. Thromb Haemostas 1987; 57: 196-200
    PubMedGoogle Scholar
  • 11 Toulon PA, Vitoux JF, Fiessinger JN, Sultan Y, Aiach M. Heparin cofactor II deficiency: a risk factor for thrombophilia?. Circulation 1988; 78 (Suppl. 02) 326 (abstract)
    PubMedGoogle Scholar
  • 12 Nerstrom B, Ladefoged J, Lund FL. Vascular complications in 155 consecutive kidney transplantations. Scand J Urol Nephrol 1972; 6 (Suppl. 15) 65-74
    CrossrefPubMedGoogle Scholar
  • 13 Ibels LS, Stewart JH, Mahony JF, Sheil AG R. Deaths from occlusive arterial disease in renal allograft recipients. Br Med J 1974; 3: 552-554
    CrossrefPubMedGoogle Scholar
  • 14 Rao KV, Smith EJ, Alexander JW, Fidler JP, Pemmaraju SR, Pollack VE. Thromboembolic disease in renal allograft recipients. Arch Surg 1976; 111: 1086-1092
    CrossrefPubMedGoogle Scholar
  • 15 Arnadottir M, Bergentz SE, Bergqvist D, Husberg B, Konrad P, Lindholm T. Thromboembolic complications after renal transplantation: a prospective analysis. World J Surg 1983; 7: 757-761
    CrossrefPubMedGoogle Scholar
  • 16 Bergqvist D, Bergentz SE, Bornmyr S, Husberg B, Konrad P, Ljungner H. Deep vein thrombosis after renal transplantation: a prospective analysis of frequency and risk factor. Eur Surg Res 1985; 17: 69-74
    PubMedGoogle Scholar
  • 17 von Kaulla KN, von Kaulla E, Wasantapruck S, Marchioro TL, Starzl TE. Blood coagulation in uremic patients before and after hemodialysis and transplantation of the kidney. Arch Surg 1966; 92: 184-191
    CrossrefPubMedGoogle Scholar
  • 18 Seitz R, Michalik R, Egbrink R, Karges HE, Lange H. Impaired fibrinolysis after kidney transplantation. Proc Eur Dial Transplant Assoc Ren Assoc 1984; 21: 941-944
    PubMedGoogle Scholar
  • 19 Dintenfass L, Ibels LS. Blood viscosity factors and occlusive arterial disease in renal transplant recipients. Nephron 1975; 15: 456-465
    CrossrefPubMedGoogle Scholar
  • 20 Cosgriff SW. Thromboembolic complications associated with ACTH and cortisone therapy. JAMA 1951; 147: 924-926
    CrossrefPubMedGoogle Scholar
  • 21 Vanrenterghem Y, Roels L, Lerut T, Gruwez J, Michielsen P, Gresele P, Deckmyn H, Colucci M, Amout J, Vermylen J. Thromboembolic complications and haemostatic changes in cyclosporine-treated cadaveric kidney allograft recipients. Lancet 1985; 01: 999-1002
    PubMedGoogle Scholar
  • 22 Gruber SA, Pescovitz MD, Simmons RL, Najarian JS, Ascher NL, Payne WD, Sutherland DE R, Fryd DS. Thromboembolic complications in renal allograft recipients: a report from the prospective randomized study of cyclosporine versus azathioprine-antilym-phocyte globulin. Transplantation 1987; 44: 775-778
    CrossrefPubMedGoogle Scholar
  • 23 Leitha T, Graninger W, Zazgornik J. Cyclosporine A does not increase the frequency of thromboembolic events. Transplant Proc 1988; 20: 436-438
    PubMedGoogle Scholar
  • 24 Gruber SA, Chavers B, Payne WD, Fryd DS, Canafax DM, Simmons RL, Najarian JS, Matas A. Allograft renal vascular thrombosis-lack of increase with cyclosporine immunosuppression. Transplantation 1989; 47: 475-478
    CrossrefPubMedGoogle Scholar
  • 25 Faulk WP, Gargiulo P, McIntyre JA, Bang NU. Hemostasis and fibrinolysis in renal transplantation. Semin Thromb Hemostas 1989; 1: 88-98
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Seitz R, Michalik R, Karges HE, Lange H, Egbring R. Impaired fibrinolysis and protein C increase after cadaver kidney transplantation. Thromb Res 1986; 42: 277-288
    CrossrefPubMedGoogle Scholar
  • 27 Brown Z, Nield GH, Willoughby JJ, Somia NV, Cameron SJ. Increased factor VIII as an index of vascular injury in cyclosporine nephrotoxicity. Transplantation 1986; 42: 150-153
    CrossrefPubMedGoogle Scholar
  • 28 Woo KT, Lee EJ C, Lau YK, Lim CH. Antithrombin III in renal transplant recipients. Thromb Res 1985; 38: 201-206
    CrossrefPubMedGoogle Scholar
  • 29 Gandrille S, Jouvin MH, Toulon P, Remy P, Fiessinger JN, Roncato M, Moatti N, Aiach M. A study of fibrinogen and fibrinolysis in 10 adults with nephrotic syndrome Thromb Haemostas 1988; 59: 445-450
    PubMed
  • 30 Toulon P, Jacquot C, Capron L, Frydman MO, Vignon D, Aiach M. Antithrombin III and heparin cofactor II in patients with chronic renal failure undergoing regular hemodialysis. Thromb Haemostas 1987; 57: 263-268
    PubMedGoogle Scholar
  • 31 Aiach M, Leon M, Michaud A, Capron L. Adaption of synthetic peptide substrate-based assays on a discrete analyzer. Semin Thromb Hemostas 1983; 9: 206-216
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestim-mung des Fibrinogens. Acta Haemtaol 1957; 17: 237-246
    PubMedGoogle Scholar
  • 33 Aiach M, Michaud A, Balian JL, Lefebvre M, Woler M, Fourtillan J. A new molecular weight heparin derivative. In vitro and in vivo studies. Thromb Res 1983; 31: 611-621
    PubMedGoogle Scholar
  • 34 Toulon P, Jacquot C, Frydman MO, Vignon D, Aiach M. Antithrombin III and heparin cofactor II in patients with chronic renal failure. Thromb Haemostas 1987; 58: 425 (Abstract).
    PubMedGoogle Scholar
  • 35 Kobayashi N, Takeda Y. Studies of the effects of estradiol, progesterone, cortisol, thrombophlebitis, and typhoid vaccine on synthesis and catabolism of antithrombin III in the dog. Thromb Haemostas 1977; 37: 111-122
    PubMedGoogle Scholar
  • 36 Sié P, Dupouy D, Pichon J, Boneu B. Turn over study of heparin cofactor II in healthy man. Thromb Haemostas 1985; 54: 635-638
    PubMedGoogle Scholar
  • 37 Sié P, Lansen J, Lacheretz F, Verschuere B, Boneu B. Comparative turnover of heparin cofactor II and antithrombin III in baboons. Influence of heparin and pentosan polysulfate administration. Thromb Haemostas 1986; 56: 302-307
    PubMedGoogle Scholar